Intervacc AB (FRA:2E9) Valuation Rank


FRA:2E9 Intervacc AB FRA:2E9
63 GF Score
Price €0.10
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is Intervacc AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Intervacc AB Valuation Rank Related Terms

FRA:2E9
63GF Score
Intervacc AB FRA:2E9
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Intervacc AB (FRA:2E9) Overvalued in 2026?

Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued. The current stock price of €0.10 is trading 22.4% above its estimated GF Value™ of €0.08.

Key valuation signals for FRA:2E9:

  • Valuation Rank:
  • GF Value™: €0.08 vs. price of €0.10 (22.4% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intervacc AB Business Description

Other Exchanges IVACC:Sweden
Address Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score

Get the complete analysis for FRA:2E9

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.08
GF Value